Trial Profile

Encorafenib and Cetuximab in Patients With Metastatic, BRAFV600E-mutated, Colorectal Carcinoma: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Encorafenib (Primary)
Indications Cancer metastases; Carcinoma; Colorectal cancer; Liver metastases
Focus Therapeutic Use
Acronyms BERING CRC
Sponsors Pierre Fabre

04 Jun 2024 Results (n=100) assessing effectiveness of Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
01 Jul 2023 Results (n=120) data collected at 56 sites across Germany, Austria, and Switzerland between 09/2020 and 11/2022, presented at the 25th World Congress on Gastrointestinal Cancer
21 Jan 2023 Planned number of patients changed from 500 to 300.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com